South Korea Pulmonary Arterial Hypertension Market Size & Outlook
South Korea pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
South Korea pulmonary arterial hypertension market highlights
- The South Korea pulmonary arterial hypertension market generated a revenue of USD 117.9 million in 2023 and is expected to reach USD 191.4 million by 2030.
- The South Korea market is expected to grow at a CAGR of 7.2% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 117.9 million |
| Market revenue in 2030 | USD 191.4 million |
| Growth rate | 7.2% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, South Korea accounted for 1.6% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- South Korea is the fastest growing regional market in Asia Pacific and is projected to reach USD 191.4 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.84% in 2023. Horizon Databook has segmented the South Korea pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
The market is driven by the increasing geriatric population and rising awareness among target populations. According to the world population ageing statistics, the elderly population contributed to 14% of the total population in 2017. The country depends on high end medical treatment. According to the report published by the PLOS One 2018, the epidemiologic data about PAH in South Korea is increasing and among them women population is more.
In the same report the data published by the Health Insurance Review and Assessment Service, which offers nationwide medical insurance of Koreans had assessed the status of PAH in Koreans. It states that from 2008–2016, 1,307 newly diagnosed with PAH and among them women are mostly prevalent.
In 2001, a rare diseases medical subsidy program was launched in the country to help manage medical expenditures. Subsequently, the government has extended provisions for patients with rare diseases and endorsed a research program. The funding program provisions low-income patients with any of 134 stated rare diseases.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
South Korea pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
South Korea Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
